OptimizeRx Corporation

What they do

OptimizeRx operates a proprietary omnichannel network that links over two million U.S. healthcare providers and millions of patients through EHR and ePrescribing platforms. Its core solutions include the AI-enabled Dynamic Audience Activation Platform (DAAP) for HCP targeting and the patent-protected Micro-Neighborhood Targeting (MNT) for privacy-centric direct-to-consumer marketing. The company generates revenue by selling tech-enabled marketing campaigns to life sciences organizations, using machine learning to identify the best audiences and channels.

Revenue drivers

• HCP marketing solutions (DAAP) — Delivers targeted messages, coupons, and co-pays to physicians through EHR and eRx platforms; historically the core revenue base.
• Direct-to-consumer marketing (MNT) — Acquired with Medicx Health in 2023; targets geographies based on de-identified claims data to reach patient audiences for brand manufacturers.
• Subscription-based data offerings — Management plans to convert DAAP and MNT customers to subscription models for data components to add recurring revenue, though not yet material.

Recent performance

For the year ended December 31, 2025, revenue grew to $109.4M from $92.1M in 2024, and the company turned profitable with net income of $5.1M versus a $20.1M loss in 2024. Operating cash flow was $18.7M in 2025, compared to $4.9M in 2024. However, quarterly revenue slowed in 2026: Q1 2026 was $19.8M and Q2 2026 was $20.5M, down from $32.2M in Q4 2025. The balance sheet at June 30, 2026 showed $24.1M cash, $17.8M long-term debt, and shareholders' equity of $131.1M.

Strategy

Management aims to become a 'Rule of 40' company by balancing growth and profitability, targeting combined revenue growth and adjusted EBITDA margin of 40% or more. A key priority is converting DAAP and MNT customers to subscription-based pricing to increase recurring revenue and EBITDA margins. The company also emphasizes innovation, customer centricity, operational excellence, and deepening relationships with top-tier pharma customers. Recent leadership changes, including a CFO transition effective January 1, 2027, are part of succession planning to support the next phase of growth.

Risks

• History of losses and profitability sustainability — The company has historically incurred losses (except 2021 and 2025) and may not sustain profitability due to ongoing investments and non-cash expenses.
• Customer concentration — Revenue depends on a concentrated group of pharmaceutical brands; loss of one or more could cause revenue to decline.
• Channel partner reliance — If contracts with eRx platforms and EHR systems are not maintained or are audited unfavorably, the business would suffer.
• Seasonal and market variability — The pharmaceutical brand marketing industry has seasonal trends that could affect quarterly operating results.

Outlook

Management expects to continue executing a land-and-expand strategy with life sciences customers and to grow a recurring revenue component through subscription conversions. The company believes these initiatives will improve EBITDA margins and revenue predictability. However, forward-looking statements acknowledge risks including potential capital needs, seasonal trends, and the challenge of sustaining profitability.